Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

IGF-1 does not affect outcome measures in phase III amyotrophic lateral sclerosis trial

Jan. 7, 2009

New mgluR2 ligands/5-HT2A antagonists described in Abbott patent

Jan. 5, 2009

Urigen amends licence agreement with UCSD for URG-101

Jan. 5, 2009

FDA issues complete response letter to Ipsen for Dysport BLA in cervical dystonia

Jan. 5, 2009

Sosei reacquires commercialization rights to opioid analgesic AD-923 from Mundipharma

Jan. 5, 2009

King commences phase II T-62 trial in neuropathic pain

Dec. 31, 2008

Neuren discontinues Glypromate development following pivotal trial

Dec. 31, 2008

AstraZeneca receives complete response letter for Seroquel XR for MDD

Dec. 31, 2008

TorreyPines describes new agents for Alzheimer's disease in recent patent

Dec. 31, 2008

Novel MGL/FAAH inhibitors emerge from sanofi-aventis R&D

Dec. 30, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...